Valeant wins Salix bidding war; Thiel invests in biotech;

@FierceBiotech: Cidara Therapeutics makes a quick leap into the growing Q1 IPO queue. News | Follow @FierceBiotech

@JohnCFierce: We're up to about 600 responses to our bull vs. bubble survey. Today's your last shot at participating. Survey | Follow @JohnCFierce

@DamianFierce: Fun fact: The NEJM paper that got PCSK9 blockade rolling was published just nine years ago. Paper | Follow @DamianFierce

> Valeant ($VRX) beat Endo ($ENDP) in a showdown for Salix Pharmaceuticals ($SLXP), agreeing to pay $173 per share in cash, or about $15.8 billion, for the North Carolina drugmaker. Story

> Silicon Valley billionaire Peter Thiel has been quietly investing in biotech startups, backing firms he believes are more than just "a lottery ticket" that's unlikely to pan out. More

> Y Combinator is backing a startup called Notable Labs that uses data analytics and robotics to spotlight potentially helpful combinations of existing drugs. Item

Medical Device News

@FierceMedDev: Metabolon rides on last year's success with $5M in extended financing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: FDA expands indication of the only sublingual second-gen antipsychotic. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Metabolon rides on last year's success with $5M in extended financing. Story | Follow @EmilyWFierce

> St. Jude releases promising data on its heart failure system. Article

> Edwards and Medtronic turn up TAVR competition with positive study data. News

Pharma News

@FiercePharma: ICYMI Friday: England to provide $GSK MenW vaccine to 3 million teens. FierceVaccines story | Follow @FiercePharma

@EricPFierce: GAO says FDA and DEA need to play better. The 2 can't even agree on what constitutes a drug shortage. FiercePharmaManufactuing article | Follow @EricPFierce

@CarlyHFierce: Endo Withdraws Proposal for Salix. Release | Follow @CarlyHFierce

> Can AstraZeneca expect big things from long-awaited Brilinta data? Maybe not, analysts say. Story

> Sorry, Endo. Valeant's back on top with $173-per-share Salix bid. Report

Animal Health News

> Aratana Therapeutics reports lower Q4, full-year 2014 financials. News

> USDA to launch national equine study this spring. Item

> Hedge fund snaps up 5% of Valeant amid speculation of a Zoetis deal. More

> New FDA report finds banned antibiotics still showing up in dairy cow tests. Story

> USDA head calls halt to any new experiments at Nebraska facility. Article

Biotech IT News

> Y Combinator backs cancer drug combo testing service. Story

> Genomics England doles out $12M as sequencing yields early breakthroughs. More

> Google adds Tute database to burgeoning Genomics platform. Report

> UCB to host epilepsy digital tool hackathon. Item

> Apple turns 700M iPhone users into potential participants in massive virtual trials. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.